These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 38186026)

    Glavatskyi O; Khranovska N; Skachkova O; Gorbach O; Khmelnytskyi H; Shuba I; Pedachenko Y; Zemskova O; Zemskova O
    Exp Oncol; 2023 Dec; 45(3):282-296. PubMed ID: 38186026
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized controlled phase II trial of vaccination with lysate-loaded, mature dendritic cells integrated into standard radiochemotherapy of newly diagnosed glioblastoma (GlioVax): study protocol for a randomized controlled trial.
    Rapp M; Grauer OM; Kamp M; Sevens N; Zotz N; Sabel M; Sorg RV
    Trials; 2018 May; 19(1):293. PubMed ID: 29801515
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictors of Response to Autologous Dendritic Cell Therapy in Glioblastoma Multiforme.
    Jan CI; Tsai WC; Harn HJ; Shyu WC; Liu MC; Lu HM; Chiu SC; Cho DY
    Front Immunol; 2018; 9():727. PubMed ID: 29910795
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DCVax-Brain and DC vaccines in the treatment of GBM.
    Wheeler CJ; Black KL
    Expert Opin Investig Drugs; 2009 Apr; 18(4):509-19. PubMed ID: 19335279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advances and challenges: dendritic cell vaccination strategies for glioblastoma.
    Schaller TH; Sampson JH
    Expert Rev Vaccines; 2017 Jan; 16(1):27-36. PubMed ID: 27500911
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Contemporary RNA Therapeutics for Glioblastoma.
    Melnick K; Dastmalchi F; Mitchell D; Rahman M; Sayour EJ
    Neuromolecular Med; 2022 Mar; 24(1):8-12. PubMed ID: 34101090
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhancing dendritic cell-based vaccination for highly aggressive glioblastoma.
    Batich KA; Swartz AM; Sampson JH
    Expert Opin Biol Ther; 2015 Jan; 15(1):79-94. PubMed ID: 25327832
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunological analysis of phase II glioblastoma dendritic cell vaccine (Audencel) trial: immune system characteristics influence outcome and Audencel up-regulates Th1-related immunovariables.
    Erhart F; Buchroithner J; Reitermaier R; Fischhuber K; Klingenbrunner S; Sloma I; Hibsh D; Kozol R; Efroni S; Ricken G; Wöhrer A; Haberler C; Hainfellner J; Krumpl G; Felzmann T; Dohnal AM; Marosi C; Visus C
    Acta Neuropathol Commun; 2018 Dec; 6(1):135. PubMed ID: 30518425
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dendritic cell vaccines for glioblastoma fail to complete clinical translation: Bottlenecks and potential countermeasures.
    Li L; Zhou J; Dong X; Liao Q; Zhou D; Zhou Y
    Int Immunopharmacol; 2022 Aug; 109():108929. PubMed ID: 35700581
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progress in active-specific immunotherapy of brain malignancies.
    Tjoa BA; Salgaller ML
    Expert Opin Investig Drugs; 2000 Sep; 9(9):2093-101. PubMed ID: 11060795
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emerging immunotherapies for glioblastoma.
    Desai R; Suryadevara CM; Batich KA; Farber SH; Sanchez-Perez L; Sampson JH
    Expert Opin Emerg Drugs; 2016 Jun; 21(2):133-45. PubMed ID: 27223671
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor Vaccines for Malignant Gliomas.
    Srinivasan VM; Ferguson SD; Lee S; Weathers SP; Kerrigan BCP; Heimberger AB
    Neurotherapeutics; 2017 Apr; 14(2):345-357. PubMed ID: 28389997
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DCVax®-L--developed by Northwest Biotherapeutics.
    Polyzoidis S; Ashkan K
    Hum Vaccin Immunother; 2014; 10(11):3139-45. PubMed ID: 25483653
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic cell-based vaccines for glioblastoma multiforme.
    Pour ME; Moghadam SG; Shirkhani P; Sahebkar A; Mosaffa F
    Med Oncol; 2023 Nov; 40(12):354. PubMed ID: 37952224
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Active dendritic cell immunotherapy for glioblastoma: Current status and challenges.
    Polyzoidis S; Tuazon J; Brazil L; Beaney R; Al-Sarraj ST; Doey L; Logan J; Hurwitz V; Jarosz J; Bhangoo R; Gullan R; Mijovic A; Richardson M; Farzaneh F; Ashkan K
    Br J Neurosurg; 2015 Apr; 29(2):197-205. PubMed ID: 25541743
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunomodulation for glioblastoma.
    Reardon DA; Wen PY; Wucherpfennig KW; Sampson JH
    Curr Opin Neurol; 2017 Jun; 30(3):361-369. PubMed ID: 28368867
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Methods behind oncolytic virus-based DC vaccines in cancer: Toward a multiphase combined treatment strategy for Glioblastoma (GBM) patients.
    Van Gool SW; Van de Vliet P; Kampers LFC; Kosmal J; Sprenger T; Reich E; Schirrmacher V; Stuecker W
    Methods Cell Biol; 2024; 183():51-113. PubMed ID: 38548421
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [What's next in glioblastoma treatment: Tumor-targeted or immune-targeted therapies?].
    Schernberg A; Marabelle A; Massard C; Armand JP; Dumont S; Deutsch E; Dhermain F
    Bull Cancer; 2016 May; 103(5):484-98. PubMed ID: 27032303
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapy of glioblastoma: Recent advances and future prospects.
    Yuan B; Wang G; Tang X; Tong A; Zhou L
    Hum Vaccin Immunother; 2022 Nov; 18(5):2055417. PubMed ID: 35344682
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dendritic cell immunotherapy for solid tumors: evaluation of the DCVax® platform in the treatment of glioblastoma multiforme.
    Hdeib A; Sloan AE
    CNS Oncol; 2015; 4(2):63-9. PubMed ID: 25768330
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.